论文部分内容阅读
目的探讨罗格列酮二甲双胍联合治疗2型糖尿病对甘露糖结合凝集素(MBL)、超敏C反应蛋白(hs-CRP)的影响。方法2型糖尿病病人47例作为观察组,其中男性26例,女性21例,予二甲双胍1g·d-1、罗格列酮4mg·d-1,共3mo。另设正常对照组,健康体健者37例,其中男性20例,女性17例。检测正常对照组、观察组治疗前后MBL和hs-CRP水平,观察组治疗前后血常规,肝、肾功能变化及不良反应。结果观察组MBL水平低于正常对照组,hs-CRP水平高于正常对照组(P<0.05)。药物干预后,观察组MBL下降(0.07±s0.20)mg·L-1、hs-CRP下降(0.7±1.2)mg·L-1,与治疗前比较有显著差异(P<0.05)。肝、肾功能无明显改变,未见严重不良反应发生。结论罗格列酮二甲双胍联合治疗可降低2型糖尿病病人MBL和hs-CRP水平。
Objective To investigate the effect of rosiglitazone combined with metformin on type 2 diabetes mellitus (MBL) and hs-CRP. Methods 47 patients with type 2 diabetes mellitus were selected as the observation group, including 26 males and 21 females, with metformin 1 g · d-1 and rosiglitazone 4 mg · d-1 for 3 months. Another set of normal control group, 37 healthy people, including 20 males and 17 females. The levels of MBL and hs-CRP in the normal control group and the observation group before and after treatment were observed, and the changes of blood routine, liver and kidney function and adverse reactions in the observation group before and after treatment were observed. Results The MBL level in the observation group was lower than that in the normal control group, and the hs-CRP level was higher in the observation group than in the normal control group (P <0.05). After drug intervention, MBL decreased (0.07 ± s0.20) mg · L-1 and decreased hs-CRP (0.7 ± 1.2) mg · L-1 in the observation group, which were significantly different from those before treatment (P <0.05). Liver, kidney function no significant change, no serious adverse reactions occurred. Conclusions Rosiglitazone combined with metformin can reduce the level of MBL and hs-CRP in type 2 diabetic patients.